Pharmacogenetic Study in Patients Received Iron Chelating Agent

NCT01623895 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2014-07-14

No results posted yet for this study

Summary

To investigate effect of genetic variations on the toxicities and find optimal target population, the investigators planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase.

Conditions

  • Hemosiderosis

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01623895 on ClinicalTrials.gov